Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.
As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.
Reports that myopericarditis may be a side effect of COVID-19 vaccination are downplayed by a recently published study that suggests there might not be a correlation.
As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.
With Spring comes new beginnings, and companies within the biopharmaceutical industry are blossoming with fresh ventures. Here are some of them:
9 Meters Biopharma has received notice from the U.S. Patent and Trademark Office (USPTO) allowing its patent for therapeutic NM-136 to treat hyperphagia (extreme hunger) and obesity.
The FDA has sprung into action, cracking down on the illegal sales of Adderall, as well as on CBD companies making claims their products are effective treatments or cures for COVID-19.
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
As Martin Shkreli, Elizabeth Holmes and Sunny Balwani, and the Purdue bankruptcy deal play out, there is even more drama beyond the stories–a failure to pay legal fees.
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
Gain Therapeutics’ candidate compound for Parkinson’s Disease demonstrated the ability to increase GCase protein levels and enhance neuronal activity.
Vertex has made a point over the past decade to make research and development a priority, investing over 70% of its expenses back into it.